See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Strand’s STX-001 receives IND clearance from FDA to treat solid tumors

Jan. 23, 2024
Strand Therapeutics Inc. has received IND clearance from the FDA to initiate a first-in-human phase I trial of STX-001 as a new approach for the treatment of solid tumors.
BioWorld Science Regulatory Cancer Immuno-oncology FDA IND